Company Overview of SARcode Bioscience Inc.
SARcode Bioscience Inc. develops small molecule compounds for the treatment of ophthalmic and dermatologic inflammations caused due to T-cells. It involves in the development of a lymphocyte function-associated antigen-antagonists for the treatment of T-cell mediated inflammatory diseases. The company was founded in 2006 and is based in Brisbane, California. As of April 17, 2013, SARcode Bioscience Inc. operates as a subsidiary of Shire plc.
1000 Marina Boulevard
Brisbane, CA 94005
Founded in 2006
Key Executives for SARcode Bioscience Inc.
SARcode Bioscience Inc. does not have any Key Executives recorded.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact SARcode Bioscience Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.